01—Abstract
Summary
Summary of the 10-Q filed August 4, 2025. Cited figures are marked; the original filing is the authoritative source.
HCA Healthcare's second quarter 2025 results show continued top-line and earnings growth.
Revenues rose 6.4% year over year to $18.605 billiona, driven by a 3.9% increase in revenue per equivalent admission and a 2.3% increase in equivalent admissions. Net income attributable to HCA rose 13.1% to $1.653 billion, or $6.83 per diluted share, versus $5.53 a year earlier, helped by a 0.2-point-lower salaries and benefits ratio and a lower effective tax rate (24.1% vs. 27.4%). Adjusted segment EBITDA across the three groups reached $4.201 billion for the quarter, up from $3.805 billion.
Share count reduction from buybacks (diluted shares down about 8.7% year over year) amplified per-share gains. Management also repurchased $5.011 billionb of stock in the first half of 2025 while maintaining a 2025 capex plan of about $5.0 billion. Balance sheet and liquidity require closer attention.
Total debt rose to $44.483 billionc from $43.031 billion at year-end 2024, and working capital turned negative at $376 million, largely due to $5.104 billion of debt due within one year and $1.778 billion of commercial paper, a new program established in June 2025. Cash fell to $939 million. Stockholders' deficit attributable to HCA widened to $(4.394) billion, reflecting heavy buybacks that exceed retained earnings growth.
Management highlighted that the July 4, 2025 One Big Beautiful Bill Act (OBBBA) is expected to reduce Medicaid coverage and federal spending over time, and that supplemental payment programs and enhanced ACA premium tax credits face expiration or restructuring risk. Management has not quantified the financial impact of these policy changes, so these remain the principal forward-looking uncertainties for investors.
Operating cash flow improved substantially to $5.861 billiond in the first half of 2025 from $4.440 billion, but about $853 million of the increase reflects a deferral of Tennessee estimated tax payments to the fourth quarter of 2025, which is a timing benefit rather than recurring earnings power. Investors should separate these timing effects from underlying cash generation.
02—Key points
Key Highlights
- Revenue grew 6.4% to $18.605 billion in Q2 2025; same-facility revenue rose 5.8%, with revenue per equivalent admission up 3.9%.
- Diluted EPS of $6.83 vs. $5.53 in Q2 2024 (up roughly 23%), supported by lower share count after buybacks and a lower effective tax rate of 24.1%.
- Total debt increased to $44.483 billion at June 30, 2025 from $43.031 billion at December 31, 2024; working capital turned negative at $(376) million, partly due to commercial paper and near-term maturities.
- Shareholders' deficit attributable to HCA widened to $(4.394) billion from $(2.499) billion, reflecting $5.011 billion of first-half share repurchases.
- First-half operating cash flow rose to $5.861 billion, but about $853 million of the gain reflects a Tennessee tax payment deferral to Q4 2025, a timing benefit.
- OBBBA, enacted July 4, 2025, is expected to reduce Medicaid enrollment and federal funding; management has not quantified the financial impact on HCA.
- Quarterly dividend declared at $0.72 per share on July 24, 2025; $5.753 billion of buyback authorization remained at June 30, 2025.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ2 FY2025filed August 4, 2025Financial Statements
Q2 FY2025 against Q2 FY2024
| Line item | Q2 FY2025Q2 FY2024 | Change |
|---|---|---|
| Revenue | $18.61B$17.49B | +6.4% |
| Operating Expenses | $16.19B$15.26B | +6.1% |
| Interest Expense | $568.00M$506.00M | +12.3% |
| Net Income | $1.65B$1.46B | +13.1% |
| EPS (Basic) | $6.91$5.60 | +23.4% |
| EPS (Diluted) | $6.83$5.53 | +23.5% |
| Shares Outstanding (Basic) | 239.17M261.16M | −8.4% |
| Shares Outstanding (Diluted) | 241.91M264.07M | −8.4% |
05—Questions
Frequently Asked Questions
How strong was HCA's operating performance in the second quarter of 2025?
Performance was solid. Revenue rose 6.4% to $18.605 billion, and income before taxes rose 8.0% to $2.415 billion. Salaries and benefits fell slightly as a share of revenue to 43.7% from 43.9%, while supplies rose to 15.3% from 15.1%, driven by medical device cost increases. Adjusted segment EBITDA increased about 10% to $4.201 billion.
Why did diluted EPS grow faster than net income?
Net income attributable to HCA grew 13.1%, while diluted EPS grew about 23%. The difference reflects a roughly 8.7% decline in diluted shares (to 241.9 million from 264.1 million) due to heavy share repurchases over the past year. Buybacks boost per-share results but reduce cash available for debt reduction or investment.
Is HCA's leverage and liquidity position a concern?
Leverage has risen. Total debt reached $44.483 billion, and the company now holds $1.778 billion of commercial paper under a new $4.0 billion program, backed by an $8.0 billion senior unsecured revolver with $6.208 billion available at June 30. Management states that operating cash flow, the revolver, and debt market access are sufficient for foreseeable needs. Investors should monitor debt maturities, interest expense (up 9.9% to $568 million in Q2), and the shrinking equity base.
What regulatory risks could affect HCA's future results?
The OBBBA is expected to reduce Medicaid eligibility through work requirements and six-month redeterminations, restrict state provider taxes, and cap state directed payments tied to Medicare rates, with grandfathering and phase-in provisions. Enhanced ACA premium tax credits are also scheduled to expire at the end of 2025. Management says it cannot yet estimate the financial impact of supplemental payment program changes. Texas and Florida account for 52% of Q2 revenue and 73% of uninsured admissions, which makes these states particularly exposed.
Were any one-time items or timing effects present in these results?
Yes. Q2 2025 included a $3 million pretax loss on facility sales, compared with a $12 million gain in Q2 2024. The effective tax rate fell in Q2 2025 largely because of unrecognized tax benefit adjustments recorded in Q2 2024. Operating cash flow benefited from roughly $853 million in deferred Tennessee estimated tax payments, which will be paid in Q4 2025, so the first-half cash flow improvement is partly temporary.
06—Continue